BioDelivery Sciences (BDSI) Acquires U.S. Commercial Rights to Symproic
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
BioDelivery Sciences Acquires U.S. Commercial Rights to Symproic®
April 10, 2019 4:05 PM EDTLong-term revenue potential of over $75 million for NME with IP protection through 2031
Leverages existing commercial capabilities to provide a novel treatment option for OICÂ
Total 2019 Company Net Sales expected to be $92-$100 million with Symproic Net Sales of $7-$9 million
Long-term potential of BELBUCA® and Symproic® combined Net Sales expected to be $325-$400 million
RALEIGH, N.C., April 10, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company... More
